Advertisement

Introduction to Soft Tissue Sarcomas

  • Ioannis P. Boukovinas
Chapter

Abstract

Soft tissue sarcomas (STS) and bone sarcomas represent 1% of all malignant tumors and comprise a diverse set of separate clinical entities with different degrees of malignancy, biological behavior, and specific therapeutic options. The incidence of STS, excluding gastrointestinal stromal tumor, is relatively low (4–5/100,000/year in Europe) [1], whereas bone sarcomas account for 0.2% of malignant tumors registered in the Eurocare database [2]. According to the Surveillance, Epidemiology, and End Results (SEER) Program and the National Center for Health Statistics, the incidence of STS is a little higher (7/100,000/year) in the United States, where, it is estimated that approximately 12,000 cases of STS and 3000 cases of bone sarcomas will be diagnosed in 2017.

References

  1. 1.
    Stiller CA, Trama A, Serraino D et al (2013) Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. Eur J Cancer 49:684–695CrossRefGoogle Scholar
  2. 2.
    Stiller CA, Craft AW, Corazziari I (2001) Survival of children with bone sarcoma in Europe since 1978: results from the EUROCARE study. Eur J Cancer 37:760–766CrossRefGoogle Scholar
  3. 3.
    Clark MA, Fisher C, Judson I et al (2005) Soft-tissue sarcomas in adults. N Engl J Med 353:701–711CrossRefGoogle Scholar
  4. 4.
    Rothermundt C, Whelan JS, Dileo P et al (2014) What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients. Br J Cancer 110:2420–2426CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Bioclinic Oncology UnitThessalonikiGreece

Personalised recommendations